pruvonertinib   Click here for help

GtoPdb Ligand ID: 13740

Synonyms: Analogue 6 [PMID: 37406381] | YK-029A
Compound class: Synthetic organic
Comment: The chemical structure for pruvonertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. A CAS number and structure match in PubChem linked the INN to the company research code YK-029A (Puhe Pharmaceutical). YK-029A was declared as an orally bioavailable EGFR inhibitor that targets receptors harbouring the T790M and exon 20 insertion (resistance) mutations in 2023 [1]. Structurally, pruvonertinib is an analogue derived from the osimertinib scaffold.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 97.16
Molecular weight 500.6
XLogP 1.12
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=NC=CC(=N2)C3=CN=C4C(=CC=CN34)C)OC)N(C)CCN(C)C
Isomeric SMILES CC1=CC=CN2C1=NC=C2C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI InChI=1S/C27H32N8O2/c1-7-25(36)30-20-15-21(24(37-6)16-22(20)34(5)14-13-33(3)4)32-27-28-11-10-19(31-27)23-17-29-26-18(2)9-8-12-35(23)26/h7-12,15-17H,1,13-14H2,2-6H3,(H,30,36)(H,28,31,32)
InChI Key OEFWUILIMFIVSE-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Liu B, Gao F, Zhao H, Yuan S, Peng X, Zhang P, Wang J, Zhang T, Duan M, Guo Y. (2023)
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.
Eur J Med Chem, 258: 115590. [PMID:37406381]